Cited by 176Pain Mechanisms and TreatmentsCancer Treatment and PharmacologyHIV/AIDS drug development and treatment

Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain

Open access
Wallace, V. C. J., Blackbeard, J., Segerdahl, A. R., Hasnie, F., Pheby, T., McMahon, S. B., Rice, A. S. C.·2007·Brain

Abstract

A distal symmetrical sensory peripheral neuropathy is frequently observed in people living with Human Immunodeficiency Virus Type 1 (HIV-1). This neuropathy can be associated with viral infection alone, probably involving a role for the envelope glycoprotein gp120; or a drug-induced toxic neuropathy associated with the use of nucleoside analogue reverse transcriptase inhibitors as a component of highly active anti-retroviral therapy. In order to elucidate the mechanisms underlying drug-induced neuropathy in the context of HIV infection, we have characterized pathological events in the peripheral and central nervous system following systemic treatment with the anti-retroviral agent, ddC (Zalcitabine) with or without the concomitant delivery of HIV-gp120 to the rat sciatic nerve (gp120+ddC). Systemic ddC treatment alone is associated with a persistent mechanical hypersensitivity (33% decrease in limb withdrawal threshold) that when combined with perineural HIV-gp120 is exacerbated (48% decrease in threshold) and both treatments result in thigmotactic (anxiety-like) behaviour. Immunohistochemical studies revealed little ddC-associated alteration in DRG phenotype, as compared with known changes following perineural HIV-gp120. However, the chemokine CCL2 is significantly expressed in the DRG of rats treated with perineural HIV-gp120 and/or ddC and there is a reduction in intraepidermal nerve fibre density, comparable to that seen in herpes zoster infection. Moreover, a spinal gliosis is apparent at times of peak behavioural sensitivity that is exacerbated in gp120+ddC as compared to either treatment alone. Treatment with the microglial inhibitor, minocycline, is associated with delayed onset of hypersensitivity to mechanical stimuli in the gp120+ddC model and reversal of some measures of thigmotaxis. Finally, the hypersensitivity to mechanical stimuli was sensitive to systemic treatment with gabapentin, morphine and the cannabinoid WIN 55,212-2, but not with amitriptyline. These data suggests that both neuropathic pain models display many features of HIV- and anti-retroviral-related peripheral neuropathy. They therefore merit further investigation for the elucidation of underlying mechanisms and may prove useful for preclinical assessment of drugs for the treatment of HIV-related peripheral neuropathic pain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awm195

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Perineural HIV-gp120 together with zalcitabine treatment resulted in mechanical allodynia greater than either treatment alone, with no changes in paw withdrawal latencies to thermal stimuli or motor deficits.

    “Perineural HIV-gp120 together with ddc treatment resulted in mechanical allodynia that was greater than either treatment alone; no changes in paw withdrawal latencies to thermal stimuli or motor deficits reported.123”
  • No hypersensitivity to thermal stimuli or motor deficits was observed following zalcitabine treatment.

    “No hypersensitivity to thermal stimuli or motor deficits was observed following ddc treatment.”
  • Rats receiving zalcitabine displayed modest gliosis whereas combined treatment with HIV-gp120 and zalcitabine increased microglial activation.

    “Rats receiving ddc displayed modest levels of gliosis whereas combined treatment with both HIV-gp120 and ddc increased levels of microglial activation.123”
  • Thigmotaxis was present in animals receiving zalcitabine, either alone or with HIV-gp120, indicating anxiety-like behavior.

    “Thigmotaxis was present in animals receiving ddc, either alone or in conjunction with HIV-gp120, indicating the presence of anxiety-like behavior in these rats.123”
  • Rats treated with zalcitabine developed mechanical allodynia that persisted up to 43 days post-injection and peaked between days 14 and 32.

    “Rats treated with the antiretroviral agent zalcitabine (ddc) developed mechanical allodynia that persisted up to 43 days post-injection and peaked between days 14 and 32.123”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Marshall S Coyle S Rice AS Ballentyne JC Pain in Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome Massachusetts General Hospital handbook of pain management 2005 446 60 Philadelphia Lippincott Williams & Wilkins
  2. Rice ASC Cannabinoids Melzack and Wall: textbook of pain 2005 521 40 London Elsevier

Cited by

Sorted by citations

Authors
Wallace, V. C. J., Blackbeard, J., Segerdahl, A. R., Hasnie, F., Pheby, T., McMahon, S. B., & Rice, A. S. C.
Affiliations
  • Chelsea and Westminster Hospital (GB)
  • Guy's Hospital (GB)
Venue
Brain
Published
2007-10-01
Volume
130
Issue
10
Pages
2688-2702
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2134914347
Cited by
176
References
91
Citations by year
2026: 2 · 2025: 6 · 2024: 5 · 2023: 8 · 2022: 8 · 2021: 11 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 5 · 2014: 24 · 2013: 17 · 2012: 11
FWCI
6.01
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • Pfizer
  • Wellcome Trust (065374)
Topics
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
HIV-associated peripheral neuropathy, HIV gp120, zalcitabine, drug-induced neuropathy, nucleoside reverse transcriptase inhibitors, antiretroviral therapy, neuropathic pain, mechanical hypersensitivity, thigmotaxis, anxiety-like behavior, dorsal root ganglia, CCL2 chemokine, minocycline, gabapentin, WIN 55,212-2
MeSH terms
Animals, Anti-Bacterial Agents, Cold Temperature, Disease Models, Animal, Epidermis, Ganglia, Spinal, Gliosis, Hot Temperature, Hyperalgesia, Male, Minocycline, Motor Activity, Nerve Fibers, Nerve Tissue Proteins, Pain Measurement, Peripheral Nervous System Diseases, Physical Stimulation, HIV Envelope Protein gp120, Zalcitabine, Rats, Wistar, Pain Threshold, Reverse Transcriptase Inhibitors, Chemokine CCL2, Anti-HIV Agents, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review